Vertex Pharmaceuticals (VRTX) Work In Process (2011 - 2012)

Vertex Pharmaceuticals (VRTX) posted quarterly Work In Process of $58.5 million for Q3 2012, up 64.45% year-over-year from $35.5 million in Q4 2011, and down 1.3% quarter-over-quarter from $59.2 million in Q2 2012.

Vertex Pharmaceuticals (VRTX) Work In Process (2011 - 2012) Analysis & Trends

Vertex Pharmaceuticals' Work In Process history runs 2 years deep, the most recent figure standing at $58.5 million for Q3 2012.

  • In Q3 2012, Work In Process rose 64.45% year-over-year to $58.5 million; the TTM figure through Sep 2012 stood at $58.5 million (up 64.45% YoY), while the FY2011 annual figure was $47.0 million, changed N/A from the prior year.
  • Work In Process for Q3 2012 stood at $58.5 million, down from $59.2 million in the prior quarter.
  • The five-year high for Work In Process was $74.7 million in Q1 2012, with the low at $10.0 million in Q1 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn

Historic Data

Download Data
DateValue
Sep 30, 2012 58.45 Mn
Jun 30, 2012 59.22 Mn
Mar 31, 2012 74.74 Mn
Dec 31, 2011 47.01 Mn
Sep 30, 2011 35.54 Mn
Mar 31, 2011 10.00 Mn